United Biotechnology (legal name: 联合生物科技（横琴）有限公司; Latin name: The United Bio-Technology (Hengqin) Co., Ltd.) is a biotechnology company based in Hengqin, Zhuhai, China.
The company focuses on the research and development of biopharmaceutical therapies, applying biotechnology to discover and develop drug candidates aimed at addressing unmet medical needs.
Triple-agonist UBT251 (GLP-1/GIP/glucagon) induced up to 9.8% weight loss, improved BP and lipids vs placebo/semaglutide. Safety consistent with triple-G class; global phase-2 and China phase-3 planned
UBT251, a triple agonist, showed significant weight loss and improved health markers in a Chinese phase 2 trial, with a safe and well-tolerated profile.
